Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.
![](/.imaging/webp/sanofi-templates/w1080-16-9/dam/campus-sanofi-qa/Article-Images/image-(94).png/jcr:content/image%20(94).png)
Related articles
MAT-BH-2300373/V1/JUNE 2023